SCHEDULE: Great Point Partners Discloses 6.06% Stake in Inventiva S.A.

Great Point Partners, along with Dr. Jeffrey R. Jay and Ms. Lillian Nordahl, reported a 6.06% beneficial ownership stake in Inventiva S.A. through a Schedule 13G filing.

Summary

• Great Point Partners, LLC, Dr. Jeffrey R. Jay, M.D., and Ms. Lillian Nordahl collectively reported beneficial ownership of 8,636,151 ordinary shares of Inventiva S.A.
• This ownership represents 6.06% of Inventiva S.A.'s total outstanding shares.
• The calculation is based on 139,151,274 common shares outstanding as of October 14, 2025, plus 3,333,332 shares issuable upon exercise of warrants held by the reporting persons, totaling 142,484,606 shares.
• The reporting persons hold 5,302,818 shares of common stock outright and warrants to purchase an additional 3,333,332 shares.
• The shares are held through Biomedical Value Fund, L.P. (BVF) and Biomedical Offshore Value Fund, Ltd. (BOVF), with Dr. Jay and Ms. Nordahl having shared voting and dispositive power.
• The reporting persons disclaim beneficial ownership of the BVF and BOVF shares except to the extent of their respective pecuniary interests.

Sentiment

Score: 7

Explanation: The disclosure of a significant institutional stake by Great Point Partners, including warrants, generally signals a positive long-term view on Inventiva S.A. from a sophisticated investor. While it's a passive filing, the commitment of capital is a positive indicator.

Positives

• A significant institutional investor, Great Point Partners, has taken a substantial stake, potentially signaling confidence in Inventiva S.A.'s long-term prospects.
• The ownership includes warrants, indicating a potential future capital injection into Inventiva S.A. if exercised, or a long-term bullish view.

Risks

• The reporting persons disclaim beneficial ownership of the underlying fund shares (BVF and BOVF) except for their pecuniary interests, which could introduce complexity in understanding ultimate control or influence.

Future Outlook

The filing does not contain specific forward-looking statements or guidance from Inventiva S.A. or the reporting persons regarding the company's future performance, beyond the implicit long-term interest suggested by the ownership stake and warrants.

Industry Context

This disclosure indicates a significant investment by a specialized healthcare investment firm, Great Point Partners, in Inventiva S.A., a biotechnology company. Such an investment suggests that experienced players in the healthcare sector see potential value in Inventiva S.A.'s pipeline or market position, aligning with broader trends of institutional interest in innovative biotech firms.

Comparison to Industry Standards

• A 6.06% stake is a notable position for an institutional investor, often indicating a strategic interest rather than a purely passive one, though the filing explicitly states the securities were not acquired for the purpose of changing or influencing control.
• This level of ownership is common for active funds in the biotech sector that seek to support growth without necessarily taking a controlling interest. Specific comparable companies or projects are not mentioned in the filing to allow for direct comparison.

Corporate Governance

Related Party Transactions

• The Joint Filing Agreement between Great Point Partners, Dr. Jeffrey R. Jay, M.D., and Ms. Lillian Nordahl formalizes their collective reporting for shared beneficial ownership.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor's stake may increase investor confidence and potentially attract further institutional interest.
• Company Management: The presence of a large institutional holder like Great Point Partners could lead to increased scrutiny or engagement regarding strategic decisions, although the filing states no intent to influence control.

Key Dates

Recommendation

The filing is a disclosure of beneficial ownership, not a financial performance report. While the significant stake by Great Point Partners, a specialized healthcare investor, is a positive signal of confidence in Inventiva S.A., it does not provide new fundamental information about the company's operations, financial health, or strategic direction to warrant a 'buy' or 'sell' recommendation. Investors should 'hold' and await further operational updates or financial results from Inventiva S.A. to make a more informed decision, while acknowledging the positive sentiment from this institutional investment.

Keywords

Inventiva S.A., Great Point Partners, Schedule 13G, Beneficial Ownership, Biotechnology, Pharmaceuticals, Institutional Investor, Equity Stake, Warrants, F5R343107